Compass Therapeutics, Inc.
Business
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics targeting angiogenesis, immune activation, and immunosuppression in solid tumors. The company's pipeline includes four clinical product candidates: tovecimig (DLL4 × VEGF-A bispecific), CTX-471 (CD137 agonist), CTX-8371 (PD-1 × PD-L1 bispecific), and CTX-10726 (PD-1 × VEGF-A bispecific), all being advanced through phase 1–3 trials in indications including biliary tract cancer, colorectal cancer, and melanoma. Compass holds worldwide commercialization rights (except limited territories for tovecimig) and relies on third-party contract manufacturers for clinical supply.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Licensing revenue | 0 | 850,000 | 0 | — | — | |
| Research and development | 56 | 42 | 38 | 30 | 20 | |
| General and administrative | 17 | 15 | 12 | 12 | 11 | |
| Total operating expenses | 73 | 57 | 50 | 42 | 82 | |
| Loss from operations | −73 | −57 | −50 | −42 | −82 | |
| Interest income | 6 | 7 | 8 | 2 | −299,000 | |
| Net loss | −66 | −49 | −42 | −39 | −82 | |
| Net loss per share - basic and diluted (in dollars per share) | −0.42 | −0.36 | −0.33 | −0.37 | −1.31 | |
| Basic and diluted weighted average shares outstanding (in shares) | 158 | 137 | 127 | 105 | 63 | |
| Unrealized gain on marketable securities | 70,000 | 173,000 | 339,000 | −302,000 | 0 | |
| Comprehensive loss | −66 | −49 | −42 | −40 | −82 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 31 | — | 44 | 24 | 35 | |
| Marketable securities | 178 | — | 83 | 128 | 152 | |
| Prepaid expenses and other current assets | 913,000 | — | 6 | 1 | 8 | |
| Total current assets | 210 | — | 133 | 154 | 195 | |
| Property and equipment, net | 102,000 | — | 353,000 | 898,000 | 2 | |
| "Operating lease, right-of-use (""ROU"") asset" | 9 | — | 7 | 2 | 3 | |
| Restricted cash | 568,000 | — | 568,000 | — | — | |
| Total assets | 220 | — | 140 | 157 | 200 | |
| Accounts payable | 2 | — | 2 | 4 | 3 | |
| Accrued expenses | 11 | — | 6 | 3 | 12 | |
| Operating lease obligations, current portion | 1 | 1 | 338,000 | 1 | 1 | |
| Total current liabilities | 14 | — | 9 | 8 | 16 | |
| Operating lease obligations, long-term portion | 9 | 9 | 6 | 536,000 | 2 | |
| Total liabilities | 23 | — | 15 | 8 | 18 | |
| Commitments and Contingencies | — | — | — | — | — | |
| Common stock, $0.0001 par value: 300,000 shares authorized; 178,324 shares issued and outstanding at December 31, 2025; 137,820 shares issued and outstanding at December 31, 2024 | 18,000 | — | 14,000 | 13,000 | 13,000 | |
| Additional paid-in-capital | 628 | — | 490 | 464 | 455 | |
| Accumulated other comprehensive income | 280,000 | — | 210,000 | 37,000 | −302,000 | |
| Accumulated deficit | −431 | — | −365 | −315 | −273 | |
| Total stockholders' equity | 197 | — | 125 | 149 | 182 | |
| Total liabilities and stockholders' equity | 220 | — | 140 | 157 | 200 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 276,000 | 589,000 | 699,000 | 782,000 | 566,000 | |
| Share-based compensation | 8 | 9 | 6 | 5 | 4 | |
| Amortization of premium and discount on marketable securities | −2 | −2 | −3 | −801,000 | 0 | |
| ROU asset amortization | 1 | 1 | 1 | 1 | 1 | |
| Prepaid expenses and other current assets | 5 | −5 | 7 | −6 | 534,000 | |
| Accounts payable | −664,000 | −2 | 708,000 | 3 | −194,000 | |
| Accrued expenses | 5 | 4 | −9 | 3 | 7 | |
| Operating lease liability | −369,000 | −1 | −1 | −1 | −1 | |
| Net cash used in operating activities | −49 | −45 | −41 | −34 | −20 | |
| Purchases of marketable securities | −195 | −88 | −155 | −200 | 0 | |
| Proceeds from sale or maturities of marketable securities | 101 | 135 | 182 | 49 | 0 | |
| Purchase of property and equipment | −25,000 | −44,000 | −30,000 | −212,000 | −2 | |
| Net cash (used in) provided by investing activities | −93 | 47 | 27 | −151 | −2 | |
| Proceeds from issuance of common stock and warrants | 138 | 18 | 3 | 76 | 128 | |
| Issuance costs from issuance of common stock | −9 | −543,000 | −94,000 | −495,000 | −281,000 | |
| Proceeds from exercise of stock options | 1 | 0 | 62,000 | 15,000 | 0 | |
| Taxes paid related to net shares settlement of RSUs | −1 | −232,000 | 159,000 | 0 | — | |
| Net cash provided by financing activities | 130 | 17 | 3 | 76 | 119 | |
| Net change in cash, cash equivalents and restricted cash | −13 | 19 | −11 | −110 | 97 | |
| Unrealized gain (loss) on marketable securities | 70,000 | 173,000 | −339,000 | 302,000 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Compass Therapeutics, Inc.'s CIK number?
Compass Therapeutics, Inc.'s SEC CIK number is 0001738021 (1738021). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Compass Therapeutics, Inc.'s SEC filings?
All of Compass Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Compass Therapeutics, Inc. last report earnings?
Compass Therapeutics, Inc. (CMPX) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001171843-26-003005). This is Compass Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Compass Therapeutics, Inc.'s most recent earnings 8-K?
Compass Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001171843-26-003005. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Compass Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →